China National Accord Medicines (SZSE:000028) Beneish M-Score: -2.38 (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:000028 China National Accord Medicines Corp Ltd SZSE:000028
57 GF Score
Price ¥20.00
! 6 Warning Signs
View Full Analysis

What is China National Accord Medicines Beneish M-Score?

China National Accord Medicines SZSE:000028 +1.01% 57 Beneish M-Score is -2.38 as of Sep. 14, 2026. GuruFocus rates SZSE:000028 with a GF Score™ of 57/100. The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, China National Accord Medicines ranks worse than 57.14% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for China National Accord Medicines's Beneish M-Score or its related term are showing as below:

SZSE:000028' s Beneish M-Score Range Over the Past 10 Years
Min: -18.51   Med: -2.43   Max: 2.71
Current: -2.38

During the past 13 years, the highest Beneish M-Score of China National Accord Medicines was 2.71. The lowest was -18.51. And the median was -2.43.


China National Accord Medicines Beneish M-Score Historical Data

* Premium members only.

The historical data trend for China National Accord Medicines's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China National Accord Medicines Beneish M-Score Chart

China National Accord Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.98 -2.68 -2.43 -2.70 -2.47

China National Accord Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.49 -2.47 -2.40 -2.38

SZSE:000028 vs MCK, COR, CAH: Beneish M-Score Comparison

For the Medical Distribution subindustry, China National Accord Medicines's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Accord Medicines Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's Beneish M-Score falls into.


SZSE:000028
57GF Score
China National Accord Medicines Corp Ltd SZSE:000028
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Accord Medicines Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China National Accord Medicines for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9811+0.528 * 1.0572+0.404 * 1.001+0.892 * 0.9931+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1114+4.679 * 0.020166-0.327 * 0.9465
=-2.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was ¥24,827 Mil.
Revenue was 18442.946 + 17823.41 + 18291.368 + 18327.892 = ¥72,886 Mil.
Gross Profit was 1867.34 + 1775.054 + 2060.529 + 1848.152 = ¥7,551 Mil.
Total Current Assets was ¥39,489 Mil.
Total Assets was ¥48,171 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,485 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,485 Mil.
Total Current Liabilities was ¥25,004 Mil.
Long-Term Debt & Capital Lease Obligation was ¥833 Mil.
Net Income was 318.741 + 287.463 + 178.808 + 291.211 = ¥1,076 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 1416.614 + -2935.333 + 2101.665 + -478.143 = ¥105 Mil.
Total Receivables was ¥25,481 Mil.
Revenue was 18503.079 + 18293.519 + 17912.14 + 18680.374 = ¥73,389 Mil.
Gross Profit was 2039.382 + 1892.405 + 2109.257 + 1997.183 = ¥8,038 Mil.
Total Current Assets was ¥40,863 Mil.
Total Assets was ¥50,426 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,083 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,346 Mil.
Total Current Liabilities was ¥27,463 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,113 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(24827.272 / 72885.616) / (25481.369 / 73389.112)
=0.340633 / 0.347209
=0.9811

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8038.227 / 73389.112) / (7551.075 / 72885.616)
=0.109529 / 0.103602
=1.0572

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (39488.673 + 2485.011) / 48170.514) / (1 - (40862.746 + 3082.673) / 50426.136)
=0.128644 / 0.128519
=1.001

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=72885.616 / 73389.112
=0.9931

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 3082.673)) / (0 / (0 + 2485.011))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1485.108 / 72885.616) / (1345.514 / 73389.112)
=0.020376 / 0.018334
=1.1114

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((833.319 + 25003.504) / 48170.514) / ((1112.669 + 27463.387) / 50426.136)
=0.536362 / 0.566691
=0.9465

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1076.223 - 0 - 104.803) / 48170.514
=0.020166

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China National Accord Medicines has a M-score of -2.38 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.38 mean?
China National Accord Medicines (SZSE:000028) has a Beneish M-Score of -2.38 as of Sep. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on China National Accord Medicines and its competitors. According to the industry distribution chart, China National Accord Medicines ranks #68 out of 119 companies in the Medical Distribution industry, placing it in the top 57.1%.
Is China National Accord Medicines' Beneish M-Score too high?
China National Accord Medicines' current Beneish M-Score is -2.38. Based on the distribution chart, China National Accord Medicines ranks #68 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, China National Accord Medicines has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Beneish M-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Accord Medicines ranks #68 out of 119 companies for Beneish M-Score. This places China National Accord Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on China National Accord Medicines and its competitors. China National Accord Medicines's current Beneish M-Score is -2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
China National Accord Medicines (SZSE:000028) has a current Beneish M-Score of -2.38. The current Beneish M-Score is -2.38. China National Accord Medicines' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For China National Accord Medicines (SZSE:000028), the current Beneish M-Score is -2.38 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China National Accord Medicines Business Description

Other Exchanges 200028:China
Address No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
57GF Score

Get the complete analysis for SZSE:000028

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.00
Price